Abstract

Malaria remained a critical global health challenge, with Plasmodium falciparum causing approximately 229 million 
cases and 409,000 deaths annually, predominantly affecting sub-Saharan Africa. Traditional artemisinin-based 
combination therapies face mounting challenges from emerging drug resistance and suboptimal pharmacokinetic 
properties. This review examined the therapeutic potential of nanoparticle-encapsulated artemisinin derivatives in 
combating P. falciparum infections, evaluating their comparative efficacy, pharmacokinetic advantages, and 
resistance prevention capabilities. A comprehensive literature review was conducted, analyzing peer-reviewed 
publications from 2018-2024, focusing on nanotechnology applications in antimalarial drug delivery systems. 
Nanoparticle encapsulation significantly enhanced artemisinin derivative bioavailability by 2.5-4.0 fold, extends 
plasma half-life from 1-2 hours to 8-12 hours, and improves targeted drug delivery to infected erythrocytes. 
Liposomal, polymeric, and lipid-based nanocarriers demonstrate superior therapeutic indices compared to 
conventional formulations. Enhanced drug concentration at target sites reduces the likelihood of resistance 
development by maintaining therapeutic levels above the minimum inhibitory concentration for extended periods. 
Clinical studies indicate improved patient compliance due to reduced dosing frequency and enhanced therapeutic 
outcomes in artemisinin-resistant malaria cases. Nanoparticle-encapsulated artemisinin derivatives represented a 
promising advancement in malaria chemotherapy, offering enhanced efficacy, improved pharmacokinetic profiles, 
and potential resistance prevention mechanisms.